Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MYOMEX-2: ulipristal acetate versus standard surgical treatment for symptomatic uterine fibroids
NL-OMON25181Recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Nov 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of ulipristal in Fibromyoma (LM) (2 arms), sponsored by Vrije University Medical Center. Primary endpoints: Fibroid-specific symptom severity at 24 months, Direct healthcare costs and 2 more. Started Nov 2018; status: recruiting.
02
Drugs
ulipristal
03
Conditions
Fibromyoma (LM)
Beyond the preview
Go deeper on NL-OMON25181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON25181.